# Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

> **NCT05621070** · PHASE3 · RECRUITING · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 582 (estimated)

## Conditions studied

- Primary Hypercholesterolaemia and Mixed Dyslipidemia

## Interventions

- **DRUG:** JS002
- **DRUG:** JS002
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05621070
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-03
- **Primary completion:** 2024-09-23
- **Final completion:** 2024-09-30
- **Target enrollment:** 582 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05621070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05621070, "Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05621070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*